1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Sawai’s Japan Core Profit Tumbles 39% As Upsher-Smith Continues Revival

Company Seeing Fewer Limits On Shipments But Still Facing Japan Headwinds

 
• By Dean Rudge

Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.

Japanese flag
Sawai must improve its fortunes in Japan before next price cuts • Source: Shutterstock

Being able to shift more drugs in its native Japan previously subject to shipment limitations was not enough for Sawai Pharmaceutical Co., Ltd. to overcome more dominant factors affecting its business in the six months to 30 September, as Japanese sales slid by 6.6% to ¥77.3bn ($550m) in the company’s 2022/2023 financial first half.

On the other hand, Sawai continued to enjoy a turnaround in fortunes for its US-based Upsher-Smith operation, which saw revenues climb sharply and a return to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.